Literature DB >> 2157519

Association of congenital hypertrophy of the retinal pigment epithelium with familial adenomatous polyposis.

T Iwama1, Y Mishima, N Okamoto, J Inoue.   

Abstract

Ophthalmological examinations were performed in 49 people (43 patients) from 24 families affected by familial adenomatous polyposis (FAP). No features of congenital hypertrophy of the retinal pigmented epithelium (CHRPE) were noted in six first-degree relatives without colonic polyps. Patients with Gardner's syndrome exhibited CHRPE more frequently than those without exostosis or desmoid tumour (91 per cent versus 45 per cent). In addition the prevalence of CHRPE was slightly higher in the patients with gastric or duodenal polyps (68 per cent compared with 50 per cent) in those who had a normal gastroduodenal examination. There were 11 families in which two or more patients underwent ophthalmological examinations. In five of these 11 families, all 12 patients were negative for CHRPE. In four of the remaining six families, all 11 patients had CHRPE. CHRPE is one of the pleiotropy of FAP and ophthalmological examination is an important screening test for the family of patients with CHRPE associated with FAP.

Entities:  

Mesh:

Year:  1990        PMID: 2157519     DOI: 10.1002/bjs.1800770312

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  10 in total

Review 1.  Familial adenomatous polyposis and inflammatory bowel disease associated in two kindreds.

Authors:  C Brignola; C Belloli; G De Simone; L Varesco; P Walger; A Areni; C Calabrese; G Di Febo; L Barbara
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

2.  The role of congenital hypertrophy of the retinal pigment epithelium in screening for familial adenomatous polyposis.

Authors:  W J Campbell; R A Spence; T G Parks
Journal:  Int J Colorectal Dis       Date:  1994       Impact factor: 2.571

3.  Genetic heterogeneity of congenital hypertrophy of the retinal pigment epithelium (CHRPE) in families with familial adenomatous polyposis.

Authors:  S V Hodgson; D T Bishop; B Jay
Journal:  J Med Genet       Date:  1994-01       Impact factor: 6.318

4.  Anticipation phenomenon in familial adenomatous polyposis:an analysis of its origin.

Authors:  Takeo Iwama; Joji Utsunomiya
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

5.  Diagnostic value of fundus examination in familial adenomatous polyposis.

Authors:  A Tiret; M Taiel-Sartral; E Tiret; L Laroche
Journal:  Br J Ophthalmol       Date:  1997-09       Impact factor: 4.638

6.  Value of the congenital hypertrophy of the retinal pigment epithelium in the diagnosis of familial adenomatous polyposis.

Authors:  Rosario Touriño; Rogelio Conde-Freire; José M Cabezas-Agrícola; Teresa Rodríguez-Aves; Maria Jesús López-Valladares; José L Otero-Cepeda; Carmen Capeans
Journal:  Int Ophthalmol       Date:  2004-03       Impact factor: 2.031

Review 7.  Familial Adenomatous Polyposis.

Authors:  Alexia Waller; Sarah Findeis; Michael J Lee
Journal:  J Pediatr Genet       Date:  2016-03-15

8.  Genotype-phenotype correlation between position of constitutional APC gene mutation and CHRPE expression in familial adenomatous polyposis.

Authors:  Y L Wallis; F Macdonald; M Hultén; J E Morton; C M McKeown; J P Neoptolemos; M Keighley; D G Morton
Journal:  Hum Genet       Date:  1994-11       Impact factor: 4.132

9.  Congenital hypertrophy of retinal pigment epithelium (CHRPE) in patients with familial adenomatous polyposis (FAP); a polyposis registry experience.

Authors:  Anwer Nusliha; Ushantha Dalpatadu; Binara Amarasinghe; Pramodh Chitral Chandrasinghe; Kemal Ismail Deen
Journal:  BMC Res Notes       Date:  2014-10-18

Review 10.  Congenital Hypertrophy of the Retinal Pigment Epithelium (CHRPE) as a Screening Marker for Familial Adenomatous Polyposis (FAP): Systematic Literature Review and Screening Recommendations.

Authors:  Louis Antoine Bonnet; R Max Conway; Li-Anne Lim
Journal:  Clin Ophthalmol       Date:  2022-03-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.